Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 623 in Systemic Lupus Erythematosus
NCT02443506Phase 1Completed
- Sponsor
- Amgen
- Start
- Oct 2004
- Primary completion
- Apr 2007
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing AMG 623 with Placebo (2 arms). Primary endpoints: Incidence of treatment emergent adverse events at 70 days, Incidence of abnormal clinically significant vital signs at 70 days and 2 more. Started Oct 2004; status: completed.
02
Drugs
blisibimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02443506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02443506.